[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Ramos et al., 2024 - Google Patents

Safety evaluation of ocular drugs

Ramos et al., 2024

Document ID
4428553070535749577
Author
Ramos M
Attar M
Seals J
Luhrs K
Publication year
Publication venue
A comprehensive guide to toxicology in nonclinical drug development

External Links

Snippet

The eye is particularly well suited for local drug delivery due to the size, location, and optical clarity of tissues and is the mainstay for the treatment of ocular conditions. There are currently 47 ocular therapeutics that are FDA approved of which 22 have been approved …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A61B3/1241—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes specially adapted for observation of ocular blood flow, e.g. by fluorescein angiography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/102—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for optical coherence tomography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/16—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for measuring intraocular pressure, e.g. tonometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Method or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Method or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/10—Eye inspection

Similar Documents

Publication Publication Date Title
Ramos et al. Safety evaluation of ocular drugs
Jonas et al. Central corneal thickness and thickness of the lamina cribrosa in human eyes
Labbé et al. The relationship between subbasal nerve morphology and corneal sensation in ocular surface disease
Mastropasqua et al. Conjunctival goblet cells density and preservative‐free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study
Peiffer Jr et al. Models in ophthalmology and vision research
EP3142664B1 (en) Compositions and methods for treating and diagnosing ocular disorders
US11865123B2 (en) Methods of inhibiting pathological angiogenesis
de Andrade et al. The autoimmune diseases of the eyes
Ramos et al. Nonproliferative and proliferative lesions of the Ratand mouse special sense organs (ocular [eye and glands], olfactory and Otic)
CN111372598A (en) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy with agents that eliminate aging cells
Ward et al. Abnormal scleral findings in uveal effusion syndrome
JP2001503370A (en) Use of (2-imidazolin-2-ylamino) quinoxaline in the treatment of ocular nerve injury
Grozdanic et al. Functional and structural changes in a canine model of hereditary primary angle-closure glaucoma
Kheirkhah et al. Subtarsal fibrosis is associated with ocular surface epitheliopathy in graft-versus-host disease
Cruzat et al. Corneal reinnervation and sensation recovery in patients with herpes zoster ophthalmicus: an in vivo and ex vivo study of corneal nerves
Pinazo-Durán et al. The role of neuroinflammation in the pathogenesis of glaucoma neurodegeneration
Tokuda et al. Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride‐Preserved Latanoprost to Preservative‐Free Tafluprost or Benzalkonium Chloride‐Preserved Tafluprost
WO2018204359A1 (en) Compositions and methods for treating ocular pathologies
Ciancaglini et al. Conjunctival modifications in ocular hypertension and primary open angle glaucoma: an in vivo confocal microscopy study
Penha et al. Retinal and ocular toxicity in ocular application of drugs and chemicals–part I: animal models and toxicity assays
Ahmed A textbook of ophthalmology
Brooks et al. Functional and structural analysis of the visual system in the rhesus monkey model of optic nerve head ischemia
CN112263670A (en) Bortezomib, application of preparation of bortezomib in preparation of medicines for treating choroidal neovascular related diseases and preparation method of eye drops
Ramos et al. Ocular immunopathology
Korbmacher et al. Feasibility of intravitreal injections and ophthalmic safety assessment in marmoset (Callithrix jacchus) monkeys